Timeline
Likang Life Sciences to open China’s first AI-assisted personalised cancer vaccine line in Beijing
AI-designed vaccine could protect against entire virus families
REPLIQA joins a crowded field betting that quantum computing can crack biology, but the science is further along than...
Mirror bacteria: the lab-made microbes scientists now fear could threaten all life on Earth
Amazon launches Bio Discovery AI for drug research
ONCOMATRYX raises $67m for Quantum ADC clinical trials
Roche deploys 3,500 NVIDIA Blackwell GPUs to embed AI across drug discovery and manufacturing
Microsoft trains AI model to convert standard pathology slides into protein maps
Google unveils new Gemini and Nano Banana model updates
Lilly inaugurates LillyPod AI supercomputer to accelerate drug discovery in Indianapolis
Palantir Beats The Street As It Upgrades Its Outlook
Microsoft researcher says AI is learning the language of biology
Biobeat Technologies raises $50 million to accelerate US rollout of cuff-less blood pressure monitor
Longevity boom reshapes investment outlook as ageing populations stay healthier for longer
Novo Nordisk launches Wegovy pill as knownwell joins NovoCare network
Bayer partners with Cradle to deploy AI platform across antibody research
Chai Discovery partners with Eli Lilly to accelerate biologics design with AI
Multiply Labs uses robotics and NVIDIA simulation to scale cell therapy manufacturing
NVIDIA expands BioNeMo platform as pharma groups commit up to $1bn to AI-driven drug discovery
Biological age tests explained: What they measure, what they miss, and how to read the results
Lab-on-a-chip explained: Tiny microfluidic devices that could shrink the laboratory
Digital twins in medicine and engineering: How to tell a useful tool from an expensive mirage
CRISPR delivery explained: Why editing DNA is easier than getting the editor to the right cells
Biofoundries explained: Inside the robot labs, engineering biology at industrial scale
New antibiotics explained: Phages, bacteriocins and AI, and why none is a silver bullet
The quiet revolution in protein design: Enzymes and binders made by algorithms, built in yeast
Organoids on a chip: Miniature human tissues that are changing how drugs are tested
Living medicines, strange ethics: the rise of engineered microbes that treat disease from the inside
The cell’s postal service: How extracellular vesicles could become the next drug delivery revolution
CRISPR’s next act: Editors that rewrite single letters without cutting the DNA
Batteries, not brains: Bioelectricity and the new map of how bodies heal
The immune system’s new teachers: Personalised cancer vaccines and the logistics of made-to-order medicine
The end of antibiotics, again: phage therapy, bacteriocins, and precision antimicrobials
Biology’s new supply chains: Why the future of biotech may be manufacturing, not discovery
Google.org awards $20m to AI-led science projects tackling health, energy and biodiversity
10X Health and Verséa unveil mitochondrial test developed from NASA research
HBO Max unveils February slate of originals, films and live sports
MoltBot Explained: The viral AI agent formerly ClawdBot
Hims & Hers to air national Big Game ad highlighting healthcare access gap
Eli Lilly to build $3.5bn weight-loss drug facility in Pennsylvania
Nvidia signals record OpenAI investment while distancing itself from $100bn figure
First human trial of cellular reprogramming approved in bid to treat blindness
Helus Pharma looks to lead a new approach to treating depression
Pfizer’s new weight-loss drug may offer monthly alternative to Wegovy and Mounjaro
BrainChild project builds precision cancer treatment platform for children in Sweden
Novo Nordisk's terrible week reveals the brutal economics of the obesity drug gold rush
A week in biotech: Four IPOs launch in a single week as Eli Lilly breaks the trillion-dollar barrier
Nvidia hosts first AI Day in Brazil as country prepares $4bn push into artificial intelligence
NVIDIA survey finds healthcare AI moving from pilots to production with measurable returns
More in AI
Shein's Hong Kong debut stumbles as China's AI-driven IPO boom leaves fast fashion behind
Shares in Shein fell more than 10% in pre-listing trading on Monday, a shaky start for the fast-fashion giant's long-delayed stock market debut.